Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

7

Revenue 2017

GlaxoSmithKline

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of GlaxoSmithKline's 2013 sales performance.

GlaxoSmithKline

FDA fast-tracks GSK’s anti-BCMA drug for multiple myeloma

FDA fast-tracks GSK’s anti-BCMA drug for multiple myeloma

If approved will become first BCMA targeting drug for myeloma. GlaxoSmithKline looks set to win the race to bring a BCMA-targeting drug to market for multiple myeloma, after gaining a

New hires at bluebird bio, BioNTech and Provention Bio

New hires at bluebird bio, BioNTech and Provention Bio She also spent 11 years at GlaxoSmithKline, ending her time there as vice president therapy area strategy and operations in the UK.

Targacept picks Solvay's Stephen Hill to fill vacant CEO post

Targacept picks Solvay's Stephen Hill to fill vacant CEO post As Targacept's president and CEO, Hill will need to refocus the firm following the termination last year of its partnership with GlaxoSmithKline – with the loss of a potential $1.5bn

Clovis leapfrogs PARP rivals, filing Rubraca for prostate cancer

Clovis leapfrogs PARP rivals, filing Rubraca for prostate cancer The filing means that Rubraca has beaten rivals such as AstraZeneca/Merck &Co’s market-leading  Lynparza (olaparib), GlaxoSmithKline/Janssen’s  Zejula (niraparib) and Pfizer’s new entrant Talzenna (talazoparib) to

FDA starts speedy review of Lynparza plus Avastin in ovarian cancer

FDA starts speedy review of Lynparza plus Avastin in ovarian cancer If the FDA backs the new indication it will help AZ and Merck to maintain their lead over newer rivals in the PARP inhibitor class, including GlaxoSmithKline’s  Zejula (niraparib), Clovis

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

White Paper for download - Explaining the price of your product
In this white paper, he breaks down the pricing options available to you, shares stories from his extensive experiences, and talks you through how to better define your pricing, step-by-step....
OPEN Health expands offering with the launch of a new Learning & Development specialist team
Enhanced expertise to deliver impactful internal training programmes for healthcare clients...
Figure 1 Clarivate
The changing nature of approvals – what does the future hold?
The 2019 CMR International Pharmaceutical R&D Factbook...

Infographics